Anthony P Sclafani1. 1. Division of Facial Plastic Surgery, The New York Eye & Ear Infirmary, New York, New York 10003, USA. asclafani@nyee.edu
Abstract
BACKGROUND: Dermal augmentation continues to grow as an aesthetic facial procedure. Many exogenous filler materials rely on an autologous fibrotic response for volume augmentation. AIMS: To evaluate the efficacy of a single injection of autologous platelet-rich fibrin matrix (PRFM) for the correction of deep nasolabial folds (NLFs). PATIENTS/ METHODS: Whole blood was obtained from 15 adults, and an activated autologous PRFM produced using a proprietary system (Selphyl; Aesthetic Factors, Inc., Wayne, NJ, USA) was then injected into the dermis and immediate subdermis below the NLFs. Subjects were photographed before and after treatment; NLFs were rated by the treating physician before and after treatment using the Wrinkle Assessment Scale (WAS) and patients rated their appearance at each post-treatment visit using the Global Aesthetic Improvement Scale. Patients were evaluated at 1, 2, 6, and 12 weeks after treatment. RESULTS: All patients were treated to maximal (no over-) correction, with a mean reduction in WAS score of 2.12 +/- 0.56. At 1 week after treatment, this difference was 0.65 +/- 0.68, but rose to 0.97 +/- 0.75, 1.08 +/- 0.59, and 1.13 +/- 0.72 at 2, 6, and 12 weeks after treatment, respectively (P < 0.001). No patient noted any fibrosis, irregularity, hardness, restricted movement, or lumpiness. CONCLUSIONS: PRFM can provide significant long-term diminution of deep NLFs without the use of foreign materials. PRFM holds significant potential for stimulated dermal augmentation.
BACKGROUND: Dermal augmentation continues to grow as an aesthetic facial procedure. Many exogenous filler materials rely on an autologous fibrotic response for volume augmentation. AIMS: To evaluate the efficacy of a single injection of autologous platelet-rich fibrin matrix (PRFM) for the correction of deep nasolabial folds (NLFs). PATIENTS/ METHODS: Whole blood was obtained from 15 adults, and an activated autologous PRFM produced using a proprietary system (Selphyl; Aesthetic Factors, Inc., Wayne, NJ, USA) was then injected into the dermis and immediate subdermis below the NLFs. Subjects were photographed before and after treatment; NLFs were rated by the treating physician before and after treatment using the Wrinkle Assessment Scale (WAS) and patients rated their appearance at each post-treatment visit using the Global Aesthetic Improvement Scale. Patients were evaluated at 1, 2, 6, and 12 weeks after treatment. RESULTS: All patients were treated to maximal (no over-) correction, with a mean reduction in WAS score of 2.12 +/- 0.56. At 1 week after treatment, this difference was 0.65 +/- 0.68, but rose to 0.97 +/- 0.75, 1.08 +/- 0.59, and 1.13 +/- 0.72 at 2, 6, and 12 weeks after treatment, respectively (P < 0.001). No patient noted any fibrosis, irregularity, hardness, restricted movement, or lumpiness. CONCLUSIONS: PRFM can provide significant long-term diminution of deep NLFs without the use of foreign materials. PRFM holds significant potential for stimulated dermal augmentation.
Authors: Gema P Sevilla; Rachita S Dhurat; Geetanjali Shetty; Prashant P Kadam; Satish M Totey Journal: Indian J Dermatol Date: 2015 Sep-Oct Impact factor: 1.494